Compare Aurora Cannabis Inc (ACB) vs TG Therapeutics Inc (TGTX) Price & Performance

Aurora Cannabis (ACB) trades at $3.82, up 32.18% amid Curaleaf's hostile takeover bid offering a 45% premium. The stock shows mixed technical signals with neutral RSI but bearish moving averages. Fundamentally, ACB achieved profitability in 2025 with $1.59M net income after years of losses, though 2026 projections show renewed negative margins. Revenue grew 27% year-over-year to $343M, but the company faces significant execution risks in a competitive cannabis market.

The takeover bid creates near-term upside potential to $4 per share, but standalone prospects remain challenged by negative profitability projections and competitive pressures. Investors face a binary outcome: accept the premium offer or risk ACB's volatile standalone execution amid declining 2026 revenue and negative margins.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.